Clinical trials: Moxifloxacin, active
Acute Appendicitis
Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis
Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure.
- Trial name
- APPACII (NCT03236961)
- Testing
- Ertapenem, Moxifloxacin
- Where
- Finland
- Volunteers
- 552 people
- Sponsor
- Turku University Hospital
Efficacy and Safety
A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
Rifampicin-resistant tuberculosis (RR-TB) is characterized by a long treatment course, high incidence of adverse reactions, low cure rate and high recurrence rate.
- Trial name
- BPaLM (NCT07126639)
- Testing
- bedaquiline, Pretomanid (Pa), linezolid
- Volunteers
- 200 people
- Sponsor
- Wuhan Pulmonary Hospital
Bronchiectasis, Non-Cystic Fibrosis
Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients
Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage.
- Trial name
- NCT07274020
- Testing
- Intermittent Moxifloxacin + Standard Care, Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Assiut University
Cataract
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
This is a multicenter, 2-arm, randomized, prospective study of patients slated for bilateral cataract extraction. One eye will be randomized to the Study Arm, and the fellow eye will be randomized to the Control Arm.
- Trial name
- NCT06681688
- Testing
- Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Inder Paul Singh, M.D.
Pulmonary Tuberculosis
A PAN-USR TB Multi-Center Trial
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide.
- Trial name
- NCT06905522
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Where
- 3 sites in China
- Volunteers
- 610 people
- Sponsor
- Shenzhen Third People's Hospital
Tuberculosis, Pulmonary
A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB
To assess outcome of treatment and safety among patients with rifampicin-resistant isoniazid-susceptible pulmonary tuberculosis treated with a novel regimen consisting of isoniazid, bedaquiline, and moxifloxacin throughout for 6…
- Trial name
- NCT06526039
- Testing
- a novel short regimen
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis in HIV-infected Individuals, Drug Susceptible Pulmonary Tuberculosis
Short-Course Regimens for DS-PTB in AIDS Patients
This study adopts a multicenter, open-label, randomized controlled design, conducted across key designated AIDS diagnosis and treatment hospitals nationwide.
- Trial name
- NCT07608172
- Testing
- 2HPMZ/2HPM, 2HRZE/4HR
- Volunteers
- 148 people
- Sponsor
- Shanghai Public Health Clinical Center
Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
The INSPIRE-TB study is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate the efficacy and safety of seven 9-month oral regimens compared to a 9-month standard of care (SOC) regimen in…
- Conditions
- Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB
- Trial name
- INSPIRE-TB (NCT05081401)
- Testing
- Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z, A1, A2a
- Where
- 5 sites in China
- Volunteers
- 1,050 people
- Sponsor
- Huashan Hospital
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Uncomplicated Acute Appendicitis
Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
APPAC IV, a randomized double-blind multicenter clinical trial comparing once daily oral moxifloxacin with placebo in an outpatient setting aims to evaluate whether antibiotics and hospitalization or both can be omitted in the…
- Trial name
- APPAC IV (NCT06210269)
- Testing
- Moxifloxacin 400mg
- Where
- 9 sites in Finland
- Volunteers
- 498 people
- Sponsor
- Turku University Hospital
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Hidradenitis Suppurativa
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
- Trial name
- ABCESS2 (NCT05821478)
- Where
- 4 sites in France
- Volunteers
- 92 people
- Sponsor
- Institut Pasteur
Mild Spinal Tuberculosis
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and…
- Trial name
- NCT06917495
- Testing
- Rifampin, Isoniazid, Rifapentine (RPT)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shandong University
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
The goal of this clinical trial is to compare the efficacy and safety of a Contezolid and Delamanid-Containing short regimen to standard longer regimen in Rifampicin-resistant pulmonary tuberculosis (RR-TB).
- Trial name
- INSPIRE-CODA (NCT06081361)
- Testing
- Bedaquiline, Delamanid, Contezolid
- Where
- 39 sites in China
- Volunteers
- 186 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
# Brief Summary This study aims to evaluate the early bactericidal activity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible…
- Trial name
- Beams (NCT07129629)
- Testing
- Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA)
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Healthy
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
- Trial name
- NCT07760246
- Testing
- Verducatib, Moxifloxacin
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Tuberculous Meningitis
Intensified Short Course Regimen for TBM in Adults
Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors.
- Trial name
- INSHORT (NCT05917340)
- Testing
- High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg
- Where
- India
- Volunteers
- 372 people
- Sponsor
- Indian Council of Medical Research
Tuberculosis, Pulmonary
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
Tuberculosis (TB) remains the most important infectious disease in the world. A major barrier to tuberculosis control is poor adherence to long-term and complex treatment regimens.
- Trial name
- ORIENT (NCT05401071)
- Testing
- Short Regimen with Rifapentine 10mg/kg, Standardized Regimen, Short Regimen with Rifapentine 15mg/kg
- Where
- 6 sites in China
- Volunteers
- 2,442 people
- Sponsor
- Huashan Hospital
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
PanACEA - STEP2C -01
This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.
- Trial name
- NCT05807399
- Testing
- BTZ-043, Rifampicin, Isoniazid
- Where
- 10 sites in Gabon, Malawi and 4 more
- Volunteers
- 390 people
- Sponsor
- Michael Hoelscher
Healthy Participants
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
A study to evaluate the safety and tolerability of single and multiple ascending doses of EPX-100 in healthy adult participants.
- Trial name
- NCT07879170
- Testing
- EPX-100, Moxifloxacin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Epygenix